TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06049420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling and coaching
Description: Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
Study: NCT05200442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A chemotherapy drug used to treat head, neck and colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A chemotherapy drug used to treat head, neck and colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A chemotherapy drug used to treat head, neck and colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A chemotherapy drug used to treat head, neck and colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A chemotherapy drug used to treat head, neck and colorectal cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pill Diary
Description: A diary where participants in phase 2 of study will log their medications and times they are taken on study.
Study: NCT06179641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective tibial nerve block
Description: The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK block
Description: The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
Study: NCT04885751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eupatilin
Description: take eupatilin to prevent NSAID induced gastroenteropathy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: take rebamipide to prevent NSAID induced gastroenteropathy
Study: NCT06313905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVADRY
Description: The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day.
Study: NCT05232487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss low back acupuncture (SLBA)
Description: Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard acupuncture (SA)
Description: Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
Study: NCT05788328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin as oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07081532
Description: PF-07081532 as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 as oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07081532
Description: PF-07081532 as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 as oral tablets
Study: NCT05448027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy
Description: It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
Study: NCT05936853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous approach to anaesthetic maintenance
Description: Anaesthetic agents given directly into the bloodstream via a cannula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational approach to anaesthetic maintenance
Description: Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
Study: NCT04210076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT-T
Description: The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBAT-I
Description: The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
Study: NCT05204407

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Luteolin
Description: The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
Study: NCT06477809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARIA Glasses ( Augmented Reality in Audio )
Description: ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARIA Glasses ( Augmented Reality in Audio )
Description: ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
Study: NCT06134271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: Rezvilutamide 240mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide plus abiraterone
Description: Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
Study: NCT05789355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUV001
Description: Daily supplementation with NUV001 at 1000 mg (4 tablets of 250 mg each) for 90 days with a prolonged follow-up of 1 month (30 days) after stopping the supplementation
Study: NCT06134271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue previous treatment
Description: Continue using the previous treatment regimen for treatment.
Study: NCT06532461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mio Advanced infusions set
Description: Insulin infusionsset fitting Medtronic 780 G insulin pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mio Advanced infusions set
Description: Insulin infusionsset fitting Medtronic 780 G insulin pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid
Description: Randomized to either Novorapid or Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid
Description: Randomized to either Novorapid or Humalog

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended wear insulin infusion (EWIS)
Description: Insulin infusionsset fitting Medtronic 780 G insulin pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended wear insulin infusion (EWIS)
Description: Insulin infusionsset fitting Medtronic 780 G insulin pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Randomized to either Novorapid or Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Randomized to either Novorapid or Humalog
Study: NCT06338696

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06572267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab low dose group
Description: Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab middle dose group
Description: Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab high dose group
Description: Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
Study: NCT06095973

Intervention type: DRUG
Group type: OTHER
Intervention: GB-6002
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: OTHER
Intervention: GB-6002
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: OTHER
Intervention: GB-6002
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: OTHER
Intervention: GB-6002
Description: Depending on the cohort, volume will be varied to administer.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.

Intervention type: DRUG
Group type: OTHER
Intervention: Naropin injection
Description: Single dose of Naropin s.c. injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Naropin injection
Description: Single dose of Naropin s.c. injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Naropin injection
Description: Single dose of Naropin s.c. injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Naropin injection
Description: Single dose of Naropin s.c. injection.
Study: NCT06095674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody balstilimab
Description: Both antibodies will be neoadjuvantly administered around the cervical tumor.
Study: NCT06175312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus properties: salience-defining feature
Description: The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus properties: magnitude of salience
Description: The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
Study: NCT06649955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-site direct current stimulation (DCS)
Description: The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
Study: NCT06650761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-622
Description: Up to 3 infusions of one of seven dosages of CDX-622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Up to 3 infusions of Normal Saline
Study: NCT06400017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microelectrode stimulation of DBS
Description: Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour
Study: NCT05915559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Tonsillectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily follow-up
Description: daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
Study: NCT06523517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat Tartrate Capsules
Description: The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
Study: NCT04758845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CGI314
Description: Subjects will consume 1B CFU of CGI314 once daily for 45 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSI08
Description: Subjects will consume 1B CFU of CSI08 once daily for 45 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MIT411
Description: Subjects will consume 1B CFU of MIT411 once daily for 45 days.
Study: NCT04857593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodies for Mums
Description: Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants.
Study: NCT05366231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kesuting syrup
Description: Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LianHuaQingWen Granules
Description: Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.
Study: NCT05789108

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample and Ultrasound examination
Description: The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff.
Study: NCT04950114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFB-887
Description: GFB-887 is a potent, small molecule inhibitor of TRPC5.
Study: NCT06400927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HF-guided VA
Description: VA guided recommendation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care
Description: Standard-of-care
Study: NCT06252389

Intervention type: PROCEDURE
Intervention: Achilles Tendon Repair augmented with Bioinductive Collagen Patch
Description: Standard Achilles Tendon Repair augmented with Bioinductive Collagen Patch. Standard Rehabilitation Protocol.